Background
Methods
Registration
Eligibility criteria
Data source and search strategy
Component | PubMed | No. of hits | EMBASE | No. of hits | Web of Science | No. of hits | WHO Global Health Library | No. of hits |
---|---|---|---|---|---|---|---|---|
Diabetes mellitus | (“Diabetes Mellitus” [mesh] OR diabetes*[tiab] OR diabetic*[tiab] OR T2DM [tiab] OR T1DM [tiab] OR “T2 DM”[tiab] OR “T1 DM”[tiab]) | 612,633 | (‘Diabetes Mellitus’/exp. OR (diabetes* OR diabetic* OR T2DM OR T1DM OR ‘T2 DM’ OR ‘T1 DM’): ab,ti) | 1,006,444 | TS = (diabetes* OR diabetic* OR T2DM OR T1DM OR “T2 DM” OR “T1 DM”) | 649,798 | ((Diabetes Mellitus) OR diabetes* OR diabetic* OR (T2DM) OR (T1DM) OR (T2 DM) OR (T1 DM)) | 670,864 |
Multi-drug-resistant tuberculosis | (“Tuberculosis, Multidrug-Resistant”[Mesh] OR ((“Tuberculosis”[Mesh] OR tubercul*[tiab] OR tb[tiab] OR antitubercul*[tiab]) AND (“Drug Resistance, Multiple”[Mesh] OR multidrug resist*[tiab] OR multi-drug resist*[tiab] OR drug resist*[tiab] OR MDR [tiab] OR multiresist*[tiab] OR multi resist*[tiab])) OR rifampcin resist*[tiab] OR MDR-TB [tiab]) | 16,247 | (‘Tuberculosis, Multidrug-Resistant’/exp. OR ((‘tuberculosis’/exp. OR (tubercul* OR tb OR antitubercul*): ab,ti) AND (‘multidrug resistance’/exp. OR (‘multidrug resist*’ OR ‘drug resist*’ OR MDR OR multiresist* OR ‘multi resist*’):ab,ti)) OR (‘rifampcin resist*’ OR MDRTB):ab,ti) | 20,105 | TS = (tubercul* OR tb OR antitubercul*) AND TS = (multidrug resist* OR drug resist* OR MDR OR multiresist* OR multi resist* OR rifampcin resist* OR MDRTB) | 17,917 | ((Tuberculosis, Multidrug-Resistant) OR ((Tuberculosis) OR tubercul* OR tb OR antitubercul* AND (multidrug resist* OR multi-drug resist* OR drug resist* OR MDR OR multiresist* OR multi resist*) OR rifampcin resist* OR MDRTB)) | 52,110 |
Combined search | #1 AND #2 | 235* | #1 AND #2 | 525* | #1 AND #2 | 254* | #1 AND #2 | 768* |
Study selection
Quality assessment and data extraction
Statistical analysis
Results
Search results
Study characteristics
Author | County | Design | Sample size (TB-DM) | Data collection procedure | DM diagnosis | Diagnosis of TB | Diagnosis of MDR-TB | TB type | DM type | OR (95% CI)†† | Adjustment to confounders |
---|---|---|---|---|---|---|---|---|---|---|---|
Baghaei P et al. [25] | Iran | CC | 282 (24) | Record review | Not specified | Not specified | Not specified | All | Type not mentioned | 0.68 (0.19–2.36) | No |
Bashar M et al. [18] | USA | CC | 155 (50) | Record review | Not specified | Not specified | Not specified | All | T1 and T2 | 5.30 (1.90–14.70) | Homelessness and HIV status |
Carreira S et al. [34] | Portugal | RC | 246 (123) | Record review | FBS/previous history of DM and receiving insulin or oral hypoglycemic agents | Not specified | Not specified | All | Type not mentioned | 1.49 (0.24–9.06) | No |
Chang JT [14] | Taiwan | PC | 192 (60) | Record review/clinical/laboratory | FBS | Clinical/chest radiographs/sputum culture (LJ media) | DST (proportional methods) | New | T2 | 6.66 (0.68–65.38) | No |
Fisher-Hoch SP et al. [50] | USA | CS | 1442 (401) | Not mentioned | Self-report | Sputum Culture | DST | All | T2 | 2.14 (1.10–4.17) | Age, gender, alcohol and drug abuse, HIV infection, history of previous TB infection |
Fisher-Hoch SP et al. [50]† | Mexico | CS | 1436 (287) | Not mentioned | Self-report | AFB/culture | DST | All | T2 | 1.80 (1.13–2.87) | Age and gender |
Gomez-Gomez A et al. [23] | Mexico | CC | 175 (56) | Record review | FBS/HbA1c | Culture/PCR for mycobacterium TB complex | DST (proportion method) | All | T1 and T2 | 2.51 (1.11–5.67) | Age, sex, smoking history, chronic alcohol abuse, malnutrition, other illness conditions |
Hafez S et al. [32] | Egypt | PC | 40 (12) | Face-to-face interview/clinical/laboratory | FBS | AFB/culture (LJ) | DST (proportional method) | All | T1 and T2 | 2.96 (0.73–11.93) | No |
Hsu A et al. [48]* | Taiwan | CS | 139 (41) | Record review/laboratory | FBS | Culture | DST (proportional method) | Previously treated | T1 and T2 | 1.52 (0.59–3.95) | Age, sex |
Hsu A et al. [48] | Taiwan | CS | 869 (204) | Record review/lab | FBS | Culture | DST (proportional method) | New | T1 and T2 | 0.95 (0.34–2.68) | Age, sex |
Jitmuang A et al. [54] | Thailand | CC | 188 (31) | Record review | Not specified | Culture (LJ) | DST (proportional method) | All | Type not mentioned | 1.28 (0.54–3.02) | No |
Magee MJ et al. [31]* | Peru | PC | 823 (143) | Record review/lab/interview | FBS/RBS/HbA1c/medication with Insulin or Oral hypoglycemic agents | AFB | DST (Griess method) | New | T1 and T2 | 0.45 (0.26–0.78) | No |
Magee MJ et al. [53] | Georgia | PC | 263 (37) | Face-to-face interview/clinical/lab | HbA1c¥ | AFB/culture (LJ)/X-ray | DST (absolute concentration method) | New | Type not mentioned | 2.27 (1.02–5.08) | Age, sex, HIV status and smoking |
Magee MJ et al. [31] | Peru | PC | 848 (43) | Record review/interview/lab | FBS/RBS/HbA1c/medication with Insulin or Oral hypoglycemic agents | AFB | DST (Griess method) | Previously treated | T1 and T2 | 1.10 (0.56–2.19) | No |
Mi F et al. [49]* | China | CS | 422 (144) | Record review | FBS | AFB/culture (LJ-media) | DST (proportional method) | New | T2 | 1.3 (0.6–2.8) | No |
Mi F et al. [49] | China | CS | 199 (43) | Record review | FBS | AFB/culture (LJ-media) | DST (proportional method) | Previously treated | T2 | 0.5 (0.2–1.1) | No |
Min J et al. [52] | Korea, Rep. | CC | 195 (55) | Record review | Record review | AFB/Chest radiographs/Culture | DST (LJ-media) | All | T1 and T2 | 2.68 (1.05–6.86) | Age and smoking |
Perez-Navarro LM et al. [19] | Mexico | CC | 409 (146) | Record review | FBS | AFB | NA | All | T2 | 3.50 (1.10–11.10) | Age |
Perez-Navarro LM et al. [30] | Mexico | PC | 507 (183) | Record review/self-report /lab | FBS | AFB | DST (BACTEC, MGIT) | New | T2 | 3.50 (1.60–7.10) | Age, sex, smoking, overcrowding |
Saktiawati AMI et al. [35] | Indonesia | RC | 356 (23) | Record review | FBS | AFB/positive chest X-ray/clinical | GeneXpert (MTB/RIF)/DST | All | T2 | ||
Rifat M et al. [20] | Bangladesh | CC | 1000 (83) | Face-to-face interview and record review | Not specified | AFB/X-ray | PCR (Xpert MTB/RIF)/culture/DST/Line probe assay | All | T2 | 2.56 (1.51–4.34) | Age, education, occupation and smoking status |
Salindri A et al. [33] | Georgia | PC | 268 (36) | Interview/lab | HbA1c | Molecular diagnostic test/AFB/culture (LJ)/clinical | DST (absolute concentration method) | New | Type not mentioned | 2.51 (1.00–6.31) | Age, sex, education, income, smoking status, alcohol use, HIV status, kidney disease |
Suarez-Garcia I et al. [21] | Spain | CC | 696 (41) | Record review | Not specified | Culture | DST (agar proportion method) | All | Type not mentioned | 1.84 (0.53–6.33) | No |
Tanrikulu A et al. [28] | Turkey | CC | 112 (9) | Record review | Not specified | Culture | DST (indirect proportion method) | All | Type not mentioned | 4.65 (1.01–21.51) | No |
Zhang Q et al. [51] | China | CS | 2141 (203) | Record review | FBS | AFB/sputum culture | DST (proportional method) | All | T1 and T2 | 2.11 (1.42–3.11) | No |
Associations between DM and MDR-TB
Study omitted | Effect size, OR | 95% CI | |
---|---|---|---|
LCL | UCL | ||
Gomez-Gomez A et al. [23] | 1.81 | 1.37 | 2.38 |
Magee MJ et al. [53] | 1.82 | 1.38 | 2.40 |
Fisher-Hoch SP et al.† [50] | 1.84 | 1.38 | 2.45 |
Hsu A et al.* [48] | 1.85 | 1.40 | 2.44 |
Saktiawati AMI et al. [35] | 1.75 | 1.36 | 2.26 |
Rifat M et al. [20] | 1.80 | 1.36 | 2.38 |
Bashar M et al. [18] | 1.76 | 1.35 | 2.29 |
Perez-Navarro LM et al. [30] | 1.77 | 1.35 | 2.33 |
Fisher-Hoch SP et al. [50] | 1.82 | 1.38 | 2.41 |
Perez-Navarro LM et al. [19] | 1.80 | 1.37 | 2.35 |
Salindri AD et al. [33] | 1.81 | 1.38 | 2.38 |
Min J et al. [52] | 1.81 | 1.37 | 2.38 |
Hsu A et al. [48] | 1.88 | 1.43 | 2.46 |
Chang JT [14] | 1.83 | 1.38 | 2.42 |
Zhang Q et al. [51] | 1.82 | 1.37 | 2.43 |
Hafez S et al. [32] | 1.81 | 1.38 | 2.38 |
Magee MJ et al.* [31] | 1.88 | 1.43 | 2.48 |
Jitmuang A et al. [54] | 1.86 | 1.41 | 2.46 |
Mi F et al.* [49] | 1.93 | 1.49 | 2.49 |
Suarez-Garcia I et al. [21] | 1.83 | 1.40 | 2.41 |
Magee MJ et al. [31] | 1.97 | 1.58 | 2.45 |
Baghaei P et al. [25] | 1.88 | 1.44 | 2.46 |
Tanrikulu A et al. [28] | 1.79 | 1.37 | 2.35 |
Mi F et al. [49] | 1.87 | 1.41 | 2.46 |
Carreira S et al. [34] | 1.84 | 1.40 | 2.41 |
Combined | 1.83 | 1.40 | 2.39 |
Study characteristics | Studies that adjusted for at least one covariate | Studies that did not adjustment for covariates | ||||||
---|---|---|---|---|---|---|---|---|
No. of studies | Pooled OR (95% CI) | I2 (%) | P value¥ | No. of studies | Pooled OR (95% CI) | I2 (%) | P value¥ | |
Study design | ||||||||
Case control | 5 | 2.89 (2.02, 4.12) | 0.0 | 0.773 | 4 | 1.39 (0.79, 2.45) | 0.0 | 0.459 |
Cohort | 4 | 3.36 (1.82, 6.20) | 40.2 | 0.171 | 3 | 1.47 (0.93, 2.34) | 0.0 | 0.501 |
Cross sectional | 4 | 1.72 (1.23, 2,41) | 19.1 | 0.250 | 4 | 1.45 (0.68, 3.09) | 73.2 | 0.011 |
Type of TB | ||||||||
Both or not defined | 7 | 2.72 (1.88, 3.94) | 38.4 | 0.136 | 7 | 1.90 (1.40, 2.60) | 0.0 | 0.492 |
New | 5 | 2.36 (1.59, 3.51) | 3.8 | 0.385 | 2 | 1.64 (0.99, 2.71) | 0.0 | 0.436 |
Previously treated | 1† | 2 | 0.77 (0.36, 1.67) | 35.4 | 0.115 | |||
Diagnosis of TB | ||||||||
Culture confirmed | 8 | 1.97 (1.51, 2.57) | 0.0 | 0.831 | 8 | 1.60 (1.08, 2.38) | 43.6 | 0.088 |
Sputum smear test only | 5 | 3.73 (2.33, 5.97) | 28.0 | 0.235 | 3 | 1.03 (0.58, 182) | 0.0 | 0.736 |
Type of DM | ||||||||
Type 2 | 6 | 2.67 (1.82, 3.93) | 40.7 | 0.134 | 3 | 1.12 (0.52, 2.42) | 67.3 | 0.047 |
Type 1 and type 2 | 5 | 2.22 (1.31, 3.76) | 35.8 | 0.183 | 3 | 1.77 (1.08, 2.89) | 35.5 | 0.212 |
Not defined | 2 | 2.37 (1.29, 4.34) | 0.0 | 0.872 | 5 | 1.46 (0.84, 2.51) | 0.0 | 0.428 |
Diagnosis of DM | ||||||||
HbA1c or FBS | 3 | 2.42 (1.49, 3.93) | 0.0 | 0.981 | 1† | |||
Only FBS | 6 | 2.68 (1.45, 4.96) | 53.5 | 0.056 | 6 | 1.50 (0.93, 2.42) | 51.6 | 0.066 |
Self-report/unspecified | 4 | 2.33 (1.65, 3.29) | 21.5 | 0.282 | 4 | 1.49 (0.77, 2.89) | 21.9 | 0.279 |
Country income level* | ||||||||
Lower middle income | 4 | 2.95 (1.69, 5.16) | 40.6 | 0.168 | 1† | |||
Upper middle income | 4 | 2.32 (1.65, 3.28) | 0.0 | 0.418 | 7 | 1.27 (0.80, 2.01) | 56.9 | 0.031 |
High income | 5 | 2.13 (1.29, 3.52) | 34.6 | 0.191 | 3 | 1.88 (1.07, 3.29) | 0.0 | 0.963 |
Overall | 13 | 2.43 (1.90, 3.12) | 19.1 | 0.250 | 11 | 1.45 (1.05, 2.02) | 35.4 | 0.115 |